S-207-115
Placed on Senate Legislative Calendar under General Orders. Calendar No. 472.
Sponsored by Amy Klobuchar (D-MN)
What it does
The SALTS Act would amend the Controlled Substances Act to specify a list of factors that prosecutors and courts may use as evidence when determining whether a synthetic drug (called a "controlled substance analogue") was intended for human consumption. Under existing law, a synthetic drug is treated as a Schedule I controlled substance — the most restricted category — only when it is intended for human consumption. This bill would clarify what kinds of evidence can be used to make that determination.
Who benefits
Federal prosecutors and law enforcement agencies, who would gain clearer legal tools to pursue charges against manufacturers and distributors of synthetic drugs (such as synthetic cannabinoids or bath salts). Communities and individuals affected by synthetic drug use could benefit if clearer evidentiary standards lead to more successful prosecutions. Judges and defense attorneys would also benefit from reduced legal ambiguity about what evidence is admissible in analogue drug cases.
Who is hurt
Manufacturers, distributors, and retailers of products that may be classified as controlled substance analogues — including some sellers of legal research chemicals or novelty products — who could face a broader or clearer basis for criminal prosecution. Defendants in analogue drug cases who previously benefited from legal ambiguity about the "intended for human consumption" standard may face a stronger evidentiary framework working against them. Civil liberties advocates argue that broader evidentiary standards could increase the risk of wrongful prosecution for individuals whose products were not genuinely intended as drugs.
Supporters argue
Supporters argue that the existing "intended for human consumption" standard in the Controlled Substances Act is too vague, allowing synthetic drug manufacturers to exploit legal loopholes by labeling dangerous products as "not for human consumption" — even when those products are clearly being sold and used as drugs. Synthetic drugs like bath salts and synthetic cannabinoids have caused thousands of emergency room visits and deaths. By codifying specific factors that courts may consider as evidence of intent, the bill would give prosecutors the tools they need to hold bad actors accountable, close a well-documented loophole, and protect public health without expanding the underlying definition of what substances are controlled.
Opponents argue
Opponents argue that codifying a broader set of evidentiary factors could lower the effective burden of proof in analogue drug prosecutions, raising due process concerns under the Fifth and Sixth Amendments. The existing analogue statute has already been criticized by courts for vagueness, and adding more factors without clear definitions may compound that problem rather than solve it. Critics also contend that the bill could sweep in legitimate researchers, chemists, or retailers of legal substances whose products share chemical similarities with controlled drugs but are not intended as substitutes. Expanding prosecutorial tools in this area, they argue, risks overcriminalization and disproportionate sentences for conduct that may not warrant Schedule I treatment.
Constitutional context
The bill implicates the Fifth Amendment's Due Process Clause, which requires that criminal statutes be written with sufficient clarity so that ordinary people can understand what conduct is prohibited (the "void for vagueness" doctrine). The Sixth Amendment's guarantee of a fair trial is relevant to evidentiary standards used against defendants. The Eighth Amendment's proportionality principle is implicated because conviction under the analogue statute triggers Schedule I penalties, which are among the most severe in federal drug law. The Fourteenth Amendment's equal protection principles may be relevant if the evidentiary factors are applied unevenly across demographic groups. Prior court challenges to the Federal Analogue Act have raised vagueness concerns, and this bill's enumerated factors could either resolve or deepen those challenges depending on how specifically the factors are defined.
Checks and balances
This bill would shift some interpretive authority from the judicial branch to the legislative branch by codifying specific evidentiary factors in statute, reducing the discretion courts currently exercise in determining what evidence is relevant to the "intended for human consumption" question. It would also strengthen the hand of the executive branch (federal prosecutors) by providing a clearer statutory framework for building analogue drug cases. Congress retains authority over the underlying scheduling and penalty structure.
Historical precedent
The Federal Analogue Act (21 U.S.C. § 813), enacted as part of the Controlled Substances Analogue Enforcement Act of 1986, established the original framework this bill amends. Courts have repeatedly grappled with the vagueness of the "intended for human consumption" standard, including in United States v. Forbes (10th Cir. 1992) and subsequent circuit-level decisions, creating the legal ambiguity this bill seeks to address.